Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07465120) titled 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase ? Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis' on March 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Dermavon Holdings Limited

Condition: Moderate to Severe Atopic Dermatitis

Intervention: Drug: CMS-D001 50mg Drug: CMS-D001 100mg Drug: CMS-D001 200mg

Recruitment Status: Not recr...